Journal of Molecular Neuroscience

, Volume 53, Issue 2, pp 183–188

Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson’s Disease

  • Natalie Kaplan
  • Aya Vituri
  • Amos D. Korczyn
  • Oren S. Cohen
  • Rivka Inzelberg
  • Gilad Yahalom
  • Evgenia Kozlova
  • Roni Milgrom
  • Yael Laitman
  • Eitan Friedman
  • Saharon Rosset
  • Sharon Hassin-Baer
Article

DOI: 10.1007/s12031-014-0276-9

Cite this article as:
Kaplan, N., Vituri, A., Korczyn, A.D. et al. J Mol Neurosci (2014) 53: 183. doi:10.1007/s12031-014-0276-9

Abstract

Levodopa-induced dyskinesias (LID) present a common but elusive complication of levodopa therapy in Parkinson’s disease (PD). In order to identify genetic factors associated with LID, 352 (213 males) levodopa-treated Israeli PD patients were genotyped for 34 polymorphisms within three candidate genes affecting dopaminergic activity and synaptic plasticity: dopamine transporter gene (DAT1 or SLC6A3) [14 single nucleotide polymorphisms (SNPs) and 40-bp variable number tandem repeat (VNTR)], DRD2 [11 SNPs and dinucleotide CA short tandem repeat (STR)], and BDNF (7 SNPs). A comparison of patients with and without LID was performed by applying a time-oriented approach, with survival analyses evaluating LID development hazard rate over time [Cox proportional hazards and accelerated failure time (AFT) lognormal models]. Overall, 192 (54.5 %) participants developed LID, with a mean latency of 5.0 (±4.5) years. After adjusting for gender, age at PD onset, duration of symptoms prior to levodopa exposure, and multiple testing correction, one SNP in SLC6A3 (with 81 % genotyping success) was significantly associated with LID latency: the C allele of the rs393795 extended the time to LID onset, time ratio = 4.96 (95 % CI, 2.3–10.9; p = 4.1 × 10−5). This finding should be validated in larger, ethnically diverse PD populations, and the biological mechanism should be explored.

Keywords

Levodopa-induced dyskinesias (LID)Parkinson’s diseaseSingle nucleotide polymorphism (SNP)Dopamine transporter gene (SLC6A3)DRD2BDNF

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Natalie Kaplan
    • 1
    • 3
  • Aya Vituri
    • 4
  • Amos D. Korczyn
    • 5
  • Oren S. Cohen
    • 1
    • 3
  • Rivka Inzelberg
    • 1
    • 3
  • Gilad Yahalom
    • 1
  • Evgenia Kozlova
    • 1
  • Roni Milgrom
    • 2
  • Yael Laitman
    • 2
  • Eitan Friedman
    • 2
    • 3
  • Saharon Rosset
    • 4
  • Sharon Hassin-Baer
    • 1
    • 3
  1. 1.The Parkinson Disease and Movement Disorders Clinic, Department of Neurology and Sagol Neuroscience CenterChaim Sheba Medical CenterRamat GanIsrael
  2. 2.The Susanne-Levy Gertner Oncogenetics Unit, The Institute of Human GeneticsChaim Sheba Medical CenterRamat GanIsrael
  3. 3.The Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  4. 4.The School of Mathematical SciencesTel Aviv UniversityTel AvivIsrael
  5. 5.The Sieratzki Chair of NeurologyTel Aviv UniversityTel AvivIsrael